Sunshine Biopharma Stock Soars 45% on Revenue Surge

Sunshine Biopharma's stock price surged to $52.88 in pre-market trading on April 2, 2025, reflecting a significant increase in investor interest and confidence in the company's recent performance and future prospects.

Sunshine Biopharma reported a substantial increase in revenue for the fiscal year 2024, reaching $34.9 million, which represents a 45% growth from the previous year's $24.1 million. This impressive financial performance was driven by the successful launch of 13 new generic prescription drugs, including four under cross-licensing agreements and nine under distribution agreements. The company also completed an underwritten public offering, raising approximately $10 million in gross proceeds to expand its sales operations.

In addition to its financial achievements, Sunshine Biopharma received regulatory approval from Health Canada for the marketing of its oncology drug NIOPEG®, a biosimilar of NEULASTA®. This approval is a significant milestone for the company, as it expands its product portfolio and enhances its market presence in the oncology sector. Furthermore, the company announced groundbreaking research results published in the Journal of Medicinal Chemistry, demonstrating the superior efficacy of its new Coronavirus PLpro inhibitor. This research highlights the company's commitment to developing innovative therapies for critical disease areas.

Sunshine Biopharma also made progress in its proprietary drug development program, completing mouse model studies that provided proof-of-concept for its K1.1 mRNA Lipid Nanoparticle as a novel therapeutic agent for human hepatocellular carcinoma. This development underscores the company's dedication to advancing its drug pipeline and addressing unmet medical needs. With these achievements, Sunshine Biopharma is well-positioned to continue its growth trajectory and deliver more life-saving medicines to the market in the coming years.